Norgestrel is a lipid of Sterol Lipids (ST) class. Norgestrel is associated with abnormalities such as Acne, Deep Vein Thrombosis, Thromboembolism, Activated Protein C Resistance and Hydrometra. The involved functions are known as Thrombosis, Aquatic environment, Venous Thrombosis, Thrombus and Inspiration function. Norgestrel often locates in Glial. The associated genes with Norgestrel are Genes, Reporter. The related lipids are Estranes.
To understand associated biological information of Norgestrel, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Norgestrel is suspected in Thromboembolism, Acne, Deep Vein Thrombosis, Activated Protein C Resistance, Hydrometra, Withdrawal bleeding and other diseases in descending order of the highest number of associated sentences.
| Disease | Cross reference | Weighted score | Related literature |
|---|
We collected disease MeSH terms mapped to the references associated with Norgestrel
| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Gynecomastia | D006177 | 6 associated lipids |
| Venous Thrombosis | D020246 | 11 associated lipids |
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
| Location | Cross reference | Weighted score | Related literatures |
|---|
| Function | Cross reference | Weighted score | Related literatures |
|---|
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
| Gene | Cross reference | Weighted score | Related literatures |
|---|
There are no associated biomedical information in the current reference collection.
| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Falcone F et al. | Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. | 2017 | J Gynecol Oncol | pmid:27670256 |
| Hasegawa S et al. | Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database. | 2017 | PLoS ONE | pmid:28732067 |
| Kiechle M and Neuenfeldt M | Experience with oral emergency contraception since the OTC switch in Germany. | 2017 | Arch. Gynecol. Obstet. | pmid:27896473 |
| Kim DH et al. | Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system. | 2017 | J Gynecol Oncol | pmid:27670255 |
| Festin MP et al. | Effect of BMI and body weight on pregnancy rates with LNG as emergency contraception: analysis of four WHO HRP studies. | 2017 | Contraception | pmid:27527670 |
| Chang T et al. | Patient or Clinician: Duration of Use of Intrauterine Devices Based on Who Initiated Discussion of Placement. | 2016 Jan-Feb | J Am Board Fam Med | pmid:26769874 |
| Gemzell-Danielsson K et al. | A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents. | 2016 | Contraception | pmid:26872720 |
| Leung VW et al. | Population-based evaluation of the effectiveness of two regimens for emergency contraception. | 2016 | Int J Gynaecol Obstet | pmid:26969148 |
| Motegi E et al. | Levonorgestrel-releasing intrauterine system placement for severe uterine cervical stenosis after conization: two case reports. | 2016 | J Med Case Rep | pmid:26960298 |
| Rowe P et al. | Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A. | 2016 | Contraception | pmid:26916172 |